SNTA Key Stats
- 3 Small Cap Cancer Stocks With Upcoming Catalysts May 20
- Synta Announces Presentations at the 2013 American Society for Clinical Oncology... May 15
- Synta Is a Run-Up Trade Into ASCO Lung Cancer Data May 14
- 3 Horrendous Health-Care Stocks This Week May 10
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin May 10
- Synta Pharmaceuticals Becomes Oversold (SNTA) May 8
- Why Synta Pharmaceuticals Shares Sank Fool May 7
- BMO Capital Downgrades Synta Pharma. (SNTA) to Market Perform Street Insider May 7
- Synta Pharma (SNTA) Sell-Off Related to R&D Pres. Resignation, Could Be Buying O... May 7
- SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events May 6
SNTA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Synta Pharmaceuticals is up 95.53% over the last year vs S&P 500 Total Return up 31.59%, SurModics up 81.82%, and Quest Diagnostics up 9.59%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for SNTA
Pro Report PDF for SNTA
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download SNTA Pro Report PDF
Pro Strategies Featuring SNTA
Did Synta Pharmaceuticals make it into our Pro Portfolio Strategies?